Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
V Möbus, G von Minckwitz, C Jackisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 12, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
S Loibl, A Schneeweiss, J Huober, et al.
Oncology (Williston Park, N.Y.)
|
February 3, 2005
Anthracycline and trastuzumab in breast cancer treatment
M Untch, I Himsl, S Kahlert, et al.
Zentralblatt Fur Gynakologie
|
December 26, 2001
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]
G von Minckwitz, G Raab, M Schütte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
R Bell, J Brown, M Parmar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2004
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial
M Untch, H Eidtmann, A du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, B M Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
G von Minckwitz, M Rezai, P A Fasching, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
V Möbus, G von Minckwitz, C Jackisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 12, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
S Loibl, A Schneeweiss, J Huober, et al.
Oncology (Williston Park, N.Y.)
|
February 3, 2005
Anthracycline and trastuzumab in breast cancer treatment
M Untch, I Himsl, S Kahlert, et al.
Zentralblatt Fur Gynakologie
|
December 26, 2001
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]
G von Minckwitz, G Raab, M Schütte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
R Bell, J Brown, M Parmar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 20, 2004
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial
M Untch, H Eidtmann, A du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, B M Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
G von Minckwitz, M Rezai, P A Fasching, et al.
Page
of 10